Cancer Research

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

Antibody drug conjugate
#Adcendo #Antibody drug conjugate (ADC) #Cancer research #Multitude Therapeutics

Agreement facilitates differentiated ADC targeting Tissue Factor 

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.  TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More

#Cancer Research #News

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics' PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. NEC is known to be the… Read More

#Cancer Research #News #Regulatory

Tumour microenvironment
#CV6 Therapeutics #Oncology #Phase I trial #Solid tumours #University of Glasgow

Investigational therapy for advanced cancers enters trials

CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More

#Cancer Research #News

Ovarian cancer cells
#Oncology #Panavance Therapeutics #PARP inhibitors #Preclinical development

New data support antitumour drug misetionamide in ovarian cancers

New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer. Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Misetionamide’s inhibition… Read More

#Cancer Research #News

#Absci #Artificial intelligence (AI) #Collaboration #Generative AI #Oncology #The Memorial Sloan Kettering Cancer Center

Partners use generative AI to develop novel cancer therapeutics

The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More

#Cancer Research #News

Human liver
#Liver cancer #National Cancer Institute #Oncology #Statins

Cholesterol-lowering drugs reduce liver cancer risk by 30%

In a new study of non-statin cholesterol-lowering medications, cholesterol absorption inhibitors were linked to lower risks of liver cancer. Cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega-3 fatty acids are types of non-statin cholesterol-lowering medications prescribed to manage cholesterol and lipid levels. The different… Read More

#Cancer Research #News

Genetics
#Colorectal cancer #Genetics / genomics #The Institute of Cancer Research #The University of Manchester #University of Leeds #University of Oxford

Genetic causes of colorectal cancer revealed in new study

A new study has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC), providing unique understanding of its response to treatment. The research was led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the… Read More

#Cancer Research #News

Antibody drug conjugate
#Angiex #Antibody drug conjugate (ADC) #Oncology #Phase I trial #Solid tumours

Antibody-drug conjugate for solid tumours enters Phase I trials

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More

#Cancer Research #News

Simon and Vanessa Conn
#Cancer treatment #circular RNAs #Flinders University #Oncology #Personalised medicine #RNA

Harnessing circRNAs could “change the landscape” of cancer therapy

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. The research was led by Senior Researcher Dr Vanessa Conn and Professor Simon Conn, who leads… Read More

#Cancer Research #Editor's Choice #News

Fusobacterium
#Bacteria #Guy’s and St Thomas' #Head and neck cancer #King's College London #Oncology

Bacteria destroys head and neck cancer tumours

Researchers at Guy’s and St Thomas’, and King’s College London in the UK have found that a bacteria is toxic for head and neck cancer and could lead to better treatments for patients. Fusobacterium is usually associated with the progression of bowel cancer. However, new research… Read More

#Cancer Research #Editor's Choice #News

Cancer cell
#Breast Cancer Now #Oncology #The Institute of Cancer Research #Treatment resistance

Science reveals how cancer cells outsmart normal cells

Scientists have discovered that some cancer cells pretend to be ‘super fit’ to fool normal healthy cells into giving them their nutrients, allowing them to expand and spread around the body. A team from The Institute of Cancer Research (ICR), London, found that ‘cheating’ cancer cells… Read More

#Cancer Research #News #Trending News

Liver cancer
#Colorectal cancer #ETH Zurich #Liver cancer #Oncology #Tumour microenvironment (TME)

Study reveals how cancer cells metastasise to the liver

Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More

#Cancer Research #News #Trending News

Cancer cells
#Cancer drug targets #Genetics / genomics #Institute of Cancer Research #Oncology #University of Cambridge #Wellcome Sanger Institute

Researchers identify potential new genetic target for cancer drugs

UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More

#Cancer Research #News #Trending News

Cancer cells
#Acute inflammatory conditions #Immuno-oncology #Oncodesign Precision Medicine #Oncology #Phase I trial

OPM tests first kinase inhibitor in clinic

Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More

#Cancer Research #News